Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) has sent an application to patent a cannabinoid medicine aimed to treat severe symptoms of epilepsy such as sudden death and seizures.
On Thursday, the cannabinoid biopharmaceutical company announced the patent application “Methods for reducing or eliminating incidence of seizures and sudden unexpected death in epilepsy” which involves a novel cannabinoid formulation to be used to treat these severe symptoms of epilepsy.
The preliminary electrophysiological in-vitro studies were led by epilepsy researcher Dr. Peter Carlen from the world-renowned Krembil Research Institute at the University Health Network.
Researchers tested the efficacy of the drug candidate and found that it was more efficient than CBD or THC alone in treating epilepsy and sudden death. Animal studies were led by Dr. Mac Burnham’s team at the University of Toronto and found similar results.
The company says it will continue to advance the new cannabinoid drug through its drug delivery platform and progress it through pre-clinical and clinical studies.
Read more: Avicanna releases pot education online portal for healthcare professionals
Read more: Avicanna and Ei.Ventures partner to commercialize fungi-based products
“The exceptional collaborative research conducted by our R&D team with Dr. Carlen’s and Dr. Burnham’s teams and the resulting patent submission will be a major driver for long-term drug and clinical development plans,” Avicanna president of research and product development Frantz Le Devedec said.
It is also a validation of the potential our scientific platform and drug pipeline have. Validating the anti-convulsant properties of our proprietary formulation in seizure disorders is important particularly since this combination drug has the potential to reduce the likelihood of seizure-induced sudden death in epilepsy patients.”
